---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-088494"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2025-06-20T23:59:59+00:00"
generated_at: "2026-05-19T01:31:42.985344+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aptevo raises $8M, reports 85% remission for mipletamig in AML, adds APVO455

## Summary
- Gross proceeds of ~$8M from registered direct offering of 2.465M shares/pre-funded warrants and 12.325M common warrants at $3.25/unit.
- Net proceeds ~$7.45M; funds for clinical development, working capital, and general corporate purposes.
- Mipletamig (CD123xCD3) shows 85% remission rate in evaluable frontline AML patients in RAINIER trial; no CRS in first two cohorts.
- Cohort 3 nears full enrollment at highest dose; mipletamig triplet therapy enables transplant in previously ineligible patient.
- New preclinical candidate APVO455 (Nectin-4xCD3) added to CD3-targeted pipeline using CRIS-7 domain; targets solid tumors.

## SEC filing metadata
- accession: 0000950170-25-088494
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2025-06-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000095017025088494/0000950170-25-088494-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000095017025088494/apvo-20250618.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-088494
- JSON: https://secwatch.observer/filing/0000950170-25-088494.json
- Plain text: https://secwatch.observer/filing/0000950170-25-088494.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.